

## **Response Letter to Reviewer's Comments**

**JOURNAL TITLE:** Mini-Reviews in Medicinal Chemistry

**MANUSCRIPT TITLE:** Osthole: A Multifunctional Natural Compound with Potential Anticancer, Antioxidant and Anti-inflammatory Activities

**Osthole: A Multifunctional Natural Compound with Potential Anticancer, Antioxidant and Anti-inflammatory Activities**

**Saba Zafar<sup>1#</sup>, Iqra Sarfraz<sup>1#</sup>, Azhar Rasul<sup>1,\*</sup>, Muhammad Ajmal Shah<sup>2,\*</sup>, Ghulam Hussain<sup>3</sup>, Muhammad Kashif Zahoor<sup>1</sup>, Nusrat Shafiq<sup>4</sup>, Ammara Riaz<sup>1</sup>, Zeliha Selamoglu<sup>5</sup>, Satyajit D. Sarker<sup>6</sup>**

<sup>1</sup>Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>2</sup>Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>3</sup>Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>4</sup>Department of Chemistry, Government College Woman University Faisalabad (GCWUF), 38000 Faisalabad, Pakistan

<sup>5</sup>Department of Medical Biology, Faculty of Medicine, Nigde Ömer Halisdemir University, Nigde, Campus 51240 Turkey

<sup>6</sup>School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, England, UK

<sup>#</sup> Authors who contributed equally in publication

**\*Corresponding authors**

1. Dr. Azhar Rasul, Assistant Professor, Cell and Molecular Biology Lab, Department of Zoology, Government College University, Faisalabad, 38000 Pakistan.

Tel: +92 3218409546, E-mail: drazharrasul@gmail.com

2. Dr. Muhammad Ajmal Shah, Assistant Professor, Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000 Pakistan.

Tel: +92 3058265476, E-mail:ajmal.shangla@gmail.com, ajmalshah@gcuf.edu.pk

### **Abstract**

Nature has always proved to be a significant reservoir of bioactive scaffolds which have been used for the discovery of drugs since times. Medicinal plants continue to be a solid niche for biologically active and therapeutically effective chemical entities, opening up new avenues for the successful treatment of several human diseases. Contribution of plant-derived compounds either in their original or semi-synthetic derivative forms extends far back in time in drug discovery. This review aims to focus on the sources, biological, and pharmacological profile of a pharmacologically active plant-derived coumarin, osthole, which is an important component of numerous remedial plants such as *Cnidium monnieri*. Several studies have revealed that osthole possess pharmacological properties such as anticancer, antioxidant, anti-hyperglycemic, neuroprotective, and antiplatelet. Osthole has been reported to regulate various signaling pathways which in turn modulate several apoptosis related proteins, cell cycle regulators, protein kinases, transcriptional factors, cytokines, and growth receptors affiliated with inflammation, proliferation and several other ailments. Osthole is known to halt proliferation and metastasis of cancerous cells by arresting the cell cycle and inducing apoptosis. The data in this review paper supports the pharmacological potential of osthole but further experimentation, biosafety profiling and synergistic effects of this compound need to be focused by the researchers to understand the full spectrum of pharmacological potential of this therapeutically potent compound.

**Keywords:** Osthole, anti-inflammatory, antioxidant, anticancer, neuroprotective



## 1. Introduction

Natural products have been utilized as therapeutic agents and act as a valuable source to invent new novel drug leads [1]. Various diseases have been cured by using the medicinal plants since prehistoric times [2-4]. “Natural products” are generally referred to as chemical entities with the origins from living organisms e.g., plants, microorganisms and marine organisms [5, 6]. Medicinal plants containing a vast range of phytochemicals including phenolics (flavonoids, coumarins, quinones, lignans, tannins, terpenoids, and stilbenes), carotenoids,  $\beta$ -carbolines (betalains, alkaloids), vitamins, and endogenous antioxidant metabolites have been reported to possess scavenging properties against free radicals [7-14]. Certain investigations have revealed that these bioactive chemical entities exhibit pharmacological properties against inflammation, tumor progression, mutagenesis, atherosclerosis, bacteria, and viruses to somewhat more or lesser extent [15-22].


*Cnidium monnieri* (L.), an important Chinese medicinal herb, from the plant family Umbelliferae is natively distributed in China, Russia, Korea and Mongolia. The dried fruits of this plant are used all over the China for curing male impotence, swelling of women's genitalia and blood stasis. The useful effects of this medicinal herb are recommended due to presence of numerous coumarin compounds [23]. Coumarins (2H-1-benzopyran-2-one) constitute a vast class of polyphenols identified in many plants, and microorganisms. This class of compounds is famous for their potential anticancer, neuroprotective, antioxidant, anti-inflammatory, antihyperglycemic, and antibacterial properties [24]. Osthole (7-methoxy-8-(3-methyl-2-butenyl)-coumarin) has caught attention in recent years due to its wide range of pharmacological and biological characteristics [25-28].

Accumulated data suggested that osthole exhibits distinct pharmacological traits including antiplatelet [29], anti-allergic [30, 31], reduction of bone loss in ovariectomized (OVX) rats [32], inhibition of systolic blood pressure [33], vasorelaxant [34], anti-inflammatory [35], anti-osteoporotic [36, 37], and anticancer [38-41] [42, 43].

The data presented in this article was collected from different electronic sites i.e., Scopus, PubMed, Sci-hub, Google Scholars, and Elsevier Science Direct. We used “osthole”, “osthole and biological activity”, “anticancer activity”, “anti-inflammatory activity”, “antioxidant”, and “neuroprotective” as key words for searching.

## 2. Natural sources of osthole

Osthole (Figure 1), a natural coumarin, has commonly been isolated from the plants of Apiaceae family such as *Angelica genuflexa* [44] and *Angelica japonica* [45]. Besides them, osthole has been reported in *Arracacia toluensis* var. *multifida* [46], *Atractylodes lancea* [47] and *Citrus aurantium* [48]. Another rich source of osthole is *C. monnieri* [49-55] which has a number of pharmacological activities including anticancer, anti-larval, anti-inflammatory, anti-diabetic, anti-hypertensive, neuroprotective, anti-osteoporosis, hyperlipidemic, anti-viral, antioxidant, antihelmintic, hepatoprotective, anti-allergic, antipruritic and vasorelaxing effects [31, 49-83]. As shown in Figure 1, osthole has also been isolated from *Clausena guillauminii* [71], *Clausena lansium* [84], *Euphorbia fischeriana* [85], *Ferulago capillaris/ brachyloba* [86], *Fructus psoralea* [87], *Heracleum rapula* [88], *Imperatoria ostruthium* [89], *Libanotis buchtormensis* [90], *Peucedanum ostruthium* [37, 91, 92], *Prangos ferulacea* [93, 94], *Radix angelicae pubescentis* [29, 62, 64, 95-103], *Siegesbeckiae herba* [104], *Seseli gummiferum* [105], and *Skimmia anquetelia* [106]. Table 1 represents biological sources of osthole and the well known therapeutic properties attributed to these medicinal plants.



**Figure 1.** Chemical structure of bioactive coumarin, osthole, and its biological sources


**Table 1.** Biological sources of osthole with their various pharmacological properties.

Plants			Parts used/ extract	Pharmacological activities	References
Scientific Name	Common Name	Native Name			
<i>Angelica genuflexa</i>	Kneeling angelica	Qu Xi Dang Gui	Roots	Antiplatelet, anti-coagulant	[44]
<i>Angelica japonica</i>	Japanese angelica	Ri Ben Dang Gui	Roots	Antiproliferative	[45]
<i>Arracacia toluensis</i> <i>var. multifidi</i>	-	-	Seeds (oils)	Antimycobacterial	[46]
<i>Atractylodes lancea</i>	-	Cangzhu	Rhizome	Anti-inflammatory	[47]
<i>Citrus aurantium</i>	Bitter orange	Zhi Shi	Fruits	Antibacterial, antifungal	[48]
<i>Cnidium monnieri</i>	Fructus cnidii	She Chuang Zi	Seeds, fruits	Antitumor, improves spatial memory deficits, anti-larval, anti-inflammatory, improves sexual dysfunction, anti-diabetes, anti-hypertensive, regulation of cardiac oxidative stress, neuroprotective, anti-osteoporosis, anti-hyperlipidemic, anti-viral, antioxidant, antihelmintic, hepatoprotective, anti-allergic, antipruritic, vasorelaxant effect	[49-55]
<i>Clausena guillauminii</i>	-	-	-	Anti-inflammatory	[71]
<i>Clausena lansium</i>	Wampee	Shí Huáng Pí	Roots	Anti-inflammatory	[84]
<i>Euphorbia fischeriana</i>	Lang du	Láng Dú Dà Jǐ	Roots	Antitumor	[85]
<i>Ferulago capillaris/brachyloba</i>	-		Roots	-	[86]
<i>Psoralea corylifolia</i>	-	Bu Gu Zhi	Seeds	Antitumor	[87]
<i>Heracleum rapula</i>	White cowparsnp	Bai Yun Hua	Roots	-	[88]
<i>Imperatoria osthuthium</i>	Masterwort	-	Seeds	-	[89]
<i>Libanotis buchtormensis</i>	-	Yan Feng	Supercritical extract	Analgesic, anti-inflammatory	[90]
<i>Peucedanum osthuthium</i>	Masterwort	Ou Qian Hu	Rhizomes	-	[92]
<i>Prangos ferulacea</i>	Ribbed cachrys	-	Roots	Antispasmodic	[93, 94]
<i>Radix angelicae pubescentis</i>	Hairy angelica root	Du Huo	Roots	Anti-inflammatory, pulmonary vasodilator, anti-diabetic, anthelmintic, vasorelaxant effect	[29, 62, 64, 95-103]
<i>Selinum cryptotaenium</i>	-	Liang She Chuang	Roots	-	[107]
<i>Siegesbeckiae herba</i>	Siegesbeckiae	Xi-Xian	Aerial parts	-	[104]

<i>Seseli gummiferum</i>	Moon carrot	-	Aerial parts	Anti-inflammatory, antinociceptive	[105]
<i>Skimmia anquetelia</i>	Magic marlot	-	Leaves	Antibacterial	[106]

### 3. Biological activities of osthole

Osthole has been documented to possess versatile range of biological as well as pharmacological properties including anticancer, antioxidant, anti-diabetic, anti-inflammatory, neuroprotective, anti-osteoporosis, vasorelaxant, and anti-thrombotic as depicted by Figure 2. Several experiments (*in vivo* as well as *in vitro*) have highlighted the pharmaceutical potential and action mechanisms of this bioactive compound.



**Figure 2.** Biological activities of osthole

#### 3.1. Osthole and its anti-inflammatory activities

The immediate defensive response of a living body against infection or pathogenic invasion in order to restore the homeostatic balance is termed as inflammation. When it happens in an unrestrained or inappropriate manner, it can cause the development of certain physiological malfunctioning incorporating cancer and many neurodegenerative diseases [108]. This uncontrolled inflammatory effect is then activated by an external bacterial endotoxin, lipopolysaccharide (LPS), which results in the stimulation of different cytokines e.g., tumor necrosis factor, interleukins, MMPs, NO, eicosanoids, and other inflammatory mediators [71].

Osthole, a natural bioactive coumarin, induces anti-inflammatory effects in various animal models as summarized in Table 2. Murine macrophage (RAW 264.7) cells, when treated with osthole, effectively inhibited inflammatory mediators such as IL-6, iNOS, TNF- $\alpha$ , NO, and COX-2. Osthole also decreased the activity of angiotensin-converting enzyme 2 (ACE2) as well as increased the activity of TRX1 (thioredoxin 1) and nuclear factor-like 2 (Nrf2) in LPS-stimulated acute lung injury [56, 71, 109]. In addition to that, osthole prohibited phosphorylation of p38 MAPK and PKC- $\alpha$  along with the suppression of NF- $\kappa$ B in LPS-treated macrophages [110].

Furthermore, osthole has potential to down-regulate the levels of myeloperoxidase (MPO), IL-1 $\beta$  and IL-8 when treated with MCAO rat model of acute ischemic stroke [111]. Moreover, administration of osthole significantly inhibited albuminuria and ameliorated renal system functions including glomerular growth and periglomerular mononuclear leukocyte infiltration in IgAN-progressive mice model. The associated mechanism involves reduction in MCP-1, superoxide anion levels, ROS inhibition and NF- $\kappa$ B activation [112].

In another study, osthole has been reported to be defensive against renal (I/R) damage as the mechanism of action of this bioactive coumarin was linked with the down-regulation of NF- $\kappa$ B signaling, TNF- $\alpha$ , IL-6, and IL-8 levels [113] while p38 MAPK expression was activated in the kidneys [9]. Further, osthole induced attenuation of hepatic injury via decreasing myeloperoxidase activity, interleukin-6 and ICAM-1 levels along with the increase in p38 MAPK phosphorylation [114]. Osthole possess promising capability to block lung inflammation on carrageenan-stimulated pleurisy in rats along with the inhibition of PMNs infiltration, reduction in MPO levels and release of inflammatory mediators such as IL-1 $\beta$  and TNF- $\alpha$  [115]. Moreover, osthole has been reported to reduce lipid accumulation via down-regulating triglyceride, total serum cholesterol, TNF- $\alpha$ , and malondialdehyde (MDA) levels as well as up-regulating GSH levels in the mice liver [116].

Osthole inhibits non-alcoholic fatty liver disease by reducing lipid augmentation via suppressing malondialdehyde concentration as well as NF- $\kappa$ B/p38 MAPK signaling pathways in FL83B cells [117]. It also showed potent anti-inflammatory effects in chronic kidney failure model of rat via decreasing NF- $\kappa$ B activity, TGF- $\beta$ 1 and monocyte chemoattractant protein-1 levels along with activation of PI3K/Akt/Nrf2 pathway [118]. In another investigation, osthole significantly



lowered RV pressure and ameliorated mitochondrial swelling, myocardial hypertrophy with sarcoplasmic reticulum amplification on MCT-mediated right ventricle (RV) rat remodeling which ultimately resulted in prohibition of myocardial inflammation [119]. Furthermore, 50  $\mu$ M and 100  $\mu$ M treatment of osthole blocked interleukin-1 $\beta$ -induced growth and migration of SW982 cells *in vitro* via inhibiting MMP-1/-3/-13, TNF- $\alpha$  and IL-6 levels along with suppressed expression of MAPK and NF- $\kappa$ B signaling cascades. It also improved collagen-mediated arthritis in a rat model *in vivo* [120]. Likewise, the protective effects of osthole were also observed in mouse microglial BV-2 cells. Results declared that osthole treatment inhibits LPS-stimulated secretion of inflammatory cytokines and activation of NF- $\kappa$ B signaling and increasing levels of HO-1 and Nrf2 in a dose-dependent way [121]. Pretreatment of osthole alleviated acetamophen-induced hepatocyte necrosis with increasing levels of ALT and AST activities along with the reduction in the inflammatory cytokines and cytochrome P450 enzymes. An increase in the expression of UGTs and SULTs was also noticed. Hence, we can conclude that osthole prevents acetamorphin-induced hepatotoxicity and exerts a preventive effect by increasing the antioxidant mechanism of liver [122]. Osthole elevated the levels of SOD2, GPX1, GCL-c, and G6pdh, and retarded the expression of AOCX and NOX2 [123]. Osthole treatment significantly reduced the secretions of TNF- $\alpha$ , IL-6 and IL-1 $\beta$  in BV2 cells stimulated by lipopolysaccharides [121].

**Table 2.** Brief outline of anti-inflammatory activities of osthole along with the molecular targets.

Assay	Organism tested	Dose/conc.	Molecular targets	References
Preventive effects of osthole on the progression of IgAN using Prg-IgAN model	Mice	50 $\mu$ M	Activation of NF- $\kappa$ B $\downarrow$ , Nrf2 $\uparrow$ , Activation of NLRP3 $\downarrow$ , MCP-1 $\downarrow$ , ROS $\downarrow$	[112]
Impacts of osthole on hepatic injury	Rats	3 mg/kg	p38 MAPK $\uparrow$ , reestablished the expression of IL-6, MPO, ICAM-1	[114]
Effects of osthole on myocardial injury	Rats	1, 10 or 50 mg/kg	HMGB1 $\downarrow$ , NF- $\kappa$ B $\downarrow$	[124]
Effect of osthole on lung injury	Mice	40 mg/kg	Trx1 $\uparrow$ , Nrf2 $\uparrow$ , H <sub>2</sub> O <sub>2</sub> $\downarrow$ , MDA $\downarrow$ , OH $\downarrow$	[56]
Effect of osthole on renal injury	Rat	40 mg/kg	MPO $\downarrow$ , IL-1 $\beta$ $\downarrow$ , TNF- $\alpha$ $\downarrow$ , p38 MAPK <sup>Act</sup>	[9]

Protective effect of osthole in lung injury in mice	Mice	40 mg/kg	TNF- $\alpha$ $\downarrow$ , IL-6 $\downarrow$	[109]
Antioxidant effects of osthole on middle cerebral artery occlusion (MCAO) on a rat model	Rats	30 mg/kg	Restoration of MCAO induced increased expression of IL-1 $\beta$ , COX-2, TNF- $\alpha$ , iNOS	[63]
Potential inflammatory activity of osthole in mouse macrophage	Macrophages	0.0086 $\pm$ 0.0024 $\mu$ M	fMLP/CB-induced superoxide anion production $\downarrow$	[35]
Osthole effects on nucleus pulposus evoking nociceptive responses through down-regulation of over expression of ASIC3	Rats	-	ASIC3 $\downarrow$	[125]
Osthole neuroprotective effects including its potential mechanisms on middle cerebral artery occlusion in rats	Rats	10, 20 and 40 mg/kg	MPO $\downarrow$ , MDA $\downarrow$ , IL-1 $\beta$ $\downarrow$ , IL-8 $\downarrow$ , GSH $\uparrow$	[111]
Inhibitory effects of osthole on expression of inflammatory mediators in murine macrophage	Murine macrophage	1, 3 and 10 $\mu$ g/mL	NO $\downarrow$ , TNF- $\alpha$ $\downarrow$ , COX-2 $\downarrow$ , p38 $\downarrow$ , p-JNK1/2 $\downarrow$ , p-PKC- $\alpha$ $\downarrow$ , p-PKC- $\epsilon$ $\downarrow$ , LPS-induced NF- $\kappa$ B activation $\downarrow$ , ROS $\downarrow$	[110]
Efficiency of osthole on IL-4-induced exotoxin expression in BEAS-2B cells	Human (BEAS-2B cells)	0.1–10 $\mu$ M	IL-4-induced STAT6 $\downarrow$	[126]
Potent inhibiting efficiency of osthole on the expression of inflammatory mediators in macrophages of mouse	Mouse (RAW 264.7) cells	10 $\mu$ M, 5 $\mu$ M	iNOS $\downarrow$ , TNF- $\alpha$ $\downarrow$ , NO $\downarrow$ , COX-2 $\downarrow$	[71]
Protective effects of osthole on lumbar disc herniation induced sciatica	Rats	50 microL 2%	COX-2 $\downarrow$ , NOS $\downarrow$	[127]
Anti-inflammatory effects of osthole and its mechanism of action in rats	Rats	50, 100 mg/kg	PG $\downarrow$ , NO $\downarrow$ , MDA $\downarrow$ , cNOS $\downarrow$ , cGMP $\uparrow$	[128]
Amelioration of inflammatory response by osthole in nonalcoholic steatohepatic rats	Rats	20 mg/kg	MCP-1 $\downarrow$ , TNF- $\alpha$ $\downarrow$ , IL-8 $\downarrow$ , IL-6 $\downarrow$	[129]
Protective effects of osthole on oleic acid induced inflammation in FL83B cells	FL83B cells	-	p-AMPK $\uparrow$ , NF- $\kappa$ B $\downarrow$ , MAPK $\downarrow$	[117]
Anti-inflammatory effects of osthole on chronic kidney failure in	Rat	40 mg/kg	TNF- $\alpha$ $\downarrow$ , IL-6 $\downarrow$ , IL-8 $\downarrow$ , NF- $\kappa$ B $\downarrow$ , TGF- $\beta$ 1 $\downarrow$	[118]

rat model				
Attenuation of inflammation by osthole in monocrotaline-induced rat model	Rats	10, 20mg/kg	TNF- $\alpha$ ↓, IL-6↓, p-NF- $\kappa$ B (p65)↓	[119]
Therapeutic effects of osthole on arthritis ( <i>in vivo</i> and <i>in vitro</i> ).	IL-1 $\beta$ -stimulated SW982 cells, collagen-induced arthritis rat model	20, 40 mg/kg ( <i>in vivo</i> ), 50, 100 $\mu$ M ( <i>in vitro</i> )	TNF- $\alpha$ ↓, IL-6 ↓, MMP-1↓, MMP-3↓, MMP-13↓, NF- $\kappa$ B↓, MAPK↓	[120]
Anti-inflammatory effects of osthole on LPS-induced inflammation in BV2 cells	BV2	10 $\mu$ g/ml	NF- $\kappa$ B↓, Nrf2↓	[121]

↑Up-regulation; ↓Down-regulation; ⊥Inhibition; <sup>Act</sup>Activation; MPO: Myeloperoxidase; Trx1: Thioredoxin 1; HMGB 1: High mobility group box protein 1; p38 MAPK: p38 mitogen activated protein kinase; ACE2: Angiotensin converting enzyme 2; NO: Nitric oxide; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ ; ASIC3: Acid sensing ion channel 3; STAT6: Signal transducer as well as activator of transcription 6; fMLP/CB: Formyl-l-methionyl-l-leucyl-l-phenylalanine/cytochalasin B

### 3.2. Osthole as neuroprotective agent

Various studies have reported that osthole also possesses neuroprotective potential. Osthole has pronounced ability to reduce cell viability losses, release of cytochrome c and LDH along with caspase-3 dose-dependently. It has also been involved in preserving the normal motor neurons by decreasing the levels of ROS. Osthole has potential capability to up-regulate Bax, activities of catalase, SOD, GSH, Erk1, and glutathione peroxidase (GPx) as well as production of adenosine triphosphate [130-132]. Osthole is involved in WNT/ $\beta$ -catenin activation which is further associated with the regulation of NSC proliferation and differentiation of neurons. This compound has also been documented as potent compound for the treatment of coronary occlusion-induced cerebral hypo-perfusion along with neural damage that can be acute especially in case of middle cerebral artery (MCA) in rats [133].

Furthermore, osthole has competency to reduce edema, MPO, infarct volume, interleukin-1 beta (IL-1 $\beta$ ), IL-8, and muscular dystrophy association (MDA) against severe strokes [111]. Moreover, myocardial I/R injury may also be cured by treatment of osthole as its mechanism of action proceeds via lowering the production of metabolites of lipid peroxidation, elevating

antioxidant abilities of enzymes, and preventing inflammation by inhibiting cytokines expression. In ischemic myocardial tissues osthole has a potential to reduce the expression of HMGBI along with NF- $\kappa$ B [124].

### 3.3. Osthole and its antioxidant activities

Byproducts of normal homeostasis and mitochondrial metabolism involve the accumulation of potentially harmful levels of ROS which needs to be formalized [134]. Imbalance among the production of ROS and cellular antioxidant defense systems results in oxidative stress. Oxidative stress is a causative factor for a variety of pathological conditions in living systems such as inflammation, endothelial dysfunction, angiogenesis, and hypertension [135].

Coumarins, a novel class of pharmacological agents, are known to strengthen the antioxidant defense systems [136]. Osthole, a naturally occurring coumarin, has promising potential to inhibit the generation of reactive oxidants such as superoxide anions [137]. This bioactive compound has competency to improve accelerated focal segmental glomerulosclerosis model at a very initial step via activation of Nrf2 with successive retardation in NF- $\kappa$ B-mediated cyclooxygenase-2 expression [138]. Accumulated data by researchers recommend that osthole has potent capability to ameliorate ischemia-reperfusion injuries in rats by suppressing oxidative stress and by strengthening antioxidant defense systems [124, 139-141]. The detail information regarding to effective inhibitory concentrations and molecular targets of osthole is provided in Table 3.

**Table 3.** Antioxidant activities of osthole and its action mechanism.

Activity	Organism tested	Dose/conc.	Mechanisms involved	References
Protective neuroprotective potential of osthole against spinal cord ischemia-reperfusion injury	Rats	10 and 50 mg/kg	The water contents of spinal cord are decreased along with volume of infarct, ROS levels reduced, ATP generation enhanced with increase in mitochondrial respiratory chain complex activities	[131]
Effect of osthole on A $\beta$ levels in neural cells and phosphorylation of CREB protein	Human (SH-SY5Y cell)	50 $\mu$ M	Intracellular A $\beta$ levels decreased in neural cells, BACE1 protein levels increased, reversed synapsin-1 reduction, reestablished phosphorylation of CREB protein	[142]
Osthole shows protective effects on middle cerebral artery	Rats	30 mg/kg	Restored the expression of MCAO induced increase in TNF-	[63]

occlusion (MCAO) model			$\alpha$ , IL-1 $\beta$ , COX-2, iNOS	
Neuroprotective role of osthole against ischemic injury ( <i>in vitro</i> )	Rats	1, 10, 50 and 100 $\mu$ M	Lowered JNK activity and increase in ERK1/2 activation	[53]
Neuroprotective potential of osthole on middle cerebral artery occlusion (MCAO) induced acute ischemic stroke in rats	Rats	10, 20 and 40 mg/kg	Increased GSH activity, decreased the volume of infarction, NDS, edema, MDA, MPO, IL-1 $\beta$ and IL-8	[111]
Protective effects of osthole on MPP (+)-induced cytotoxicity in PC12 cells	Rats	0.01, 0.05, 0.10 mM	Increased Bax/Bcl-2 ratio, reduced LDH release, decreased cytochrome c and caspase-3 activity, cell viability losses reduced	[68]
Effectiveness of osthole on chronic cerebral hypo-perfusion induced neuronal degeneration and cognitive impairment in hippocampus of rats	Rats	10, 20 mg/kg	Decreased production of malondialdehyde (MDA), decreased bax/bcl-2 ratio, increased activities of GPx and CAT	[130]
Protective effect of osthole and associated mechanism on learning and memory impairment in mice	Mice	15 and 7.5 mg.kg <sup>-1</sup>	Enhanced activities of GSH-PX and SOD	[143]
Antioxidant effects of osthole in FL83B cells	FL83B cells	-	Blockage of NF- $\kappa$ B and MAPK signaling pathways	[117]
Efficacy of osthole against a rat model of hypoperfused retina	Rats	40 mg/kg	Reduction of NF- $\kappa$ B and Akt levels, Increased ratio of Bcl-2/Bax, Enhanced activities of SOD	[144]
Attenuation of type 2 diabetes in mice induced by streptozotocin and high-fat diet	Mice	20mg/kg	Increased insulin levels, enhanced activities of glutathione peroxidase, superoxide dismutase, catalase	[145]
Antioxidant effects of osthole against dinitrobenzene sulphonic acid induced-colitis in rats	Rats	50 mg/kg	Increased MDA and MPO, GSH, CAT and SOD levels	[146]

### 3.4. Osthole and its anticancer activities

Predestined and genetically modulated cell suicide activity is termed as apoptosis [147, 148]. Various complex signals are involved in this process e.g., DISC (Death-inducing signaling complex). DISC can promote DNA fragmentation, biochemical, and morphological aberrations such as membrane blebbing [149, 150].

Phytochemicals, from medicinal plants, are thought to be the most significant reservoirs for the discovery of anticancer drugs [151]. Studies have revealed that osthole shows synergetic effects on cell proliferation and tumor inhibition in different types of cancers.

Many studies on osthole have reported its antiproliferative traits because of its promising potential to induce apoptosis in different cancerous cells [152, 153] including prostatic cancer

(LNCaP, PC3, DU145) [154], leukemia (HL-60) [155], lung cancer cells (A549) [41] [156], breast cancer (MDA-MB 231, MCF-7) [69], hepatocellular cancer (HepG2, SK-LU-1) [54, 157, 158], epidermal carcinoma (KB) [54], human laryngeal cancer (RK33), medulloblastoma cell (TE671) [159], glioma cancer cells (U87) [160], colorectal cell line (CoLo 205) [155], nasopharyngeal carcinoma [161], esophageal [162], gastric [163], and colon cancer cells (HCT116, SW480) [164].

Osthole has potential capability to trigger apoptosis, to arrest cell cycle at S/G2 phases, to regulate TP53 gene expression and CDKN1A depending on cancer cells dose-dependently [159]. Treatment of hepatocellular cancer cell lines with osthole inhibited activity of NF- $\kappa$ B with the ultimate inhibition of tumor growth and induction of apoptosis [157]. Osthole's ability to prevent the multiplication of osteosarcoma (MG-63) cells is linked with the suppression of Bcl-2 while up-regulating Bax levels [165]. It can also inhibit the metastatic activity in lung adenocarcinoma cells (CL1-5, H1299) via inhibition of MMP-9 and I $\kappa$ B $\alpha$  degradation [166]. In case of glioblastoma multiforme (GBM), osthole blocked metastatic transformation occurs by inhibition of IGF-1-induced EMT along with blockage of PI3K/Akt pathway [167]. Osthole prohibited invasion and migration in AIPC cells *in vitro*, while metastasis of AIPC during *in vivo* studies in rats [168]. Osthole inhibited TGF- $\beta$ /Smads signaling and regulated the OPG/RANKL signals in breast cancer cells [27].

Several investigations have documented that osthole is involved in arresting cell cycle at G1 phase in lung cancer cells [169] and in breast cancer (MDA-MB 435) cells via down-regulating Cdk2 and cyclin D1, along with the up-regulation of p21Waf1/Cip1 and p53 [170]. While in A549 cells, osthole induced arrest at G2/M phase by suppressing cyclin B1, Bcl-2 and p-Cdc2 expression, up-regulating the Bax expression and inhibiting PI3K/Akt signaling pathway [41]. Findings from an *in vitro* study has reported induction of apoptosis by osthole via suppressing NF- $\kappa$ B activity in liver cancer cells (Figure 3) [157].

#### 3.4.1. Osthole and AMPK/PI3K/Akt and ERK Pathway

ERK (Extracellular signal regulated kinase) signaling cascade performs a significant function in the progression and development of tumors. Key factor of ERK pathway is ERK1/2, whose inhibition prevents tumor cell propagation. Phosphoinositide 3 kinase (PI3K)/Akt signaling network has also been associated with cell survival, proliferation and angiogenesis and is most

common signal transduction pathway activated during cancer [30, 171]. PI3K/Akt is also known to be a potential target for the cure of breast and several other cancer types [172]. These signaling pathways consist of several kinase cascades, which can be phosphorylated and de-phosphorylated by specific enzymes including phosphatases and adaptor proteins [30].

Natural compounds are known to specifically target various signaling pathways which perform an imperative function in cancer development and progression [169]. Treatment of osthole as an anticancer agent in A549 cells has declared the fact that it has significant potential to attenuate the phosphorylation of two crucial pro-survival kinases, ERK and Akt. Osthole is also involved in inhibiting the activation of AMPK which suggests that it can be a novel anticancer drug candidate for the treatment of lung cancer [173].

Osthole also has an ability to induce G2/M phase arrest and apoptosis in A549 cells via modulating the activity of PI3K/Akt signaling [41]. Phosphorylation of Akt, an important PI3K downstream target, was decreased in C6 cells after the administration of osthole [174]. Treatment of human brain cancer cells by osthole leads to the inhibition of IGF-1 stimulated EMT via blockage of PI3K/Akt pathway (Figure 3) [167]. During an *in vitro* investigation, osthole inhibited the proliferation of esophageal cancer cells via modulation of PTEN-PI3K/Akt signaling pathway [162]. In cholangiocarcinoma HCCC-9810 and RBE cancer cells, osthole down-regulated the expression of PI3K and phosphorylation level of Akt which contributed towards the osthole-induced apoptosis in these cells [175]. Thus, it is suggested that osthole has potential to induce mitochondrial-dependent apoptosis through PI3K/Akt signaling cascade [175].

#### 3.4.2. Targeting NF- $\kappa$ B with osthole

NF- $\kappa$ B is widely accepted as an important player for cancer initiation and progression as it supplies oncogenic signals to tumor cells. Thus, this signaling cascade epitomizes a tempting target for cancer prevention [176].

It has been proved by multitudinous studies that osthole actively participates in the prevention of invasive and migratory capabilities of human lung CL1-5 cells by NF- $\kappa$ B pathway inhibition which can lead to the down-regulated MMP-9 levels [166]. Osthole has ability to suppress cellular proliferation in hepatocellular carcinoma cells via suppression of NF- $\kappa$ B in the dose-and

time-dependent manner [157]. Osthole was also noticed to reduce the cell viability, proliferation, migration, and invasion of cervical cancer cells dose dependently. It inhibited NF- $\kappa$ B activity while increasing the levels of E-cadherin and decreasing the levels of vimentin, thereby suggesting osthole as a therapeutic candidate for an adjuvant treatment for cervical cancer [177]

#### *3.4.3. Targeting p53 with osthole*

Mutated p53 gene is one of the crucial necessities for tumor initiation or development. Reviving the effectiveness of aberrant p53 through small molecules is an auspicious approach to combat cancer [178] [179, 180].

It has been reported that osthole is capable of inducing apoptosis and cell cycle arrest in breast cancer (MDA-MB 453) cells. The attempt to understand the underlying action mechanism of osthole has highlighted the fact that it significantly stimulates G1 phase arresting because of increasing activity of p21/p53 and reducing expression of cyclin D1 and Cdk2 (Figure 3) [170]. p53, a cell cycle regulatory protein, is a significant mediator for osthole-induced cancer prevention. Osthole has ability to activate p53 gene via up-regulating p53 phosphorylation on Ser15 (p-p53) and p53 acetylation on Lys379 (acetyl-p53) [164]. Osthole in HepG2 cells induced arrest at G2/M phase of cell cycle and ultimately triggered apoptosis by enhanced levels of pro-apoptotic Bax and p53 (Figure 3) [181].


#### *3.4.4. Role of osthole in inhibition of tumor metastasis*

One of the most fundamental challenges involved in curing cancer is tumor metastasis which is regarded as the transfer of tumorigenic cells from originative site to far-off organs for colonization [182, 183].

Matrix metalloproteinase-9 induction is specifically crucial for tumor metastasis in many cancers. Osthole, a pharmacologically active coumarin caused effective inhibition of the invasive ability of A549 cells via reduced expression of NF- $\kappa$ B mediated expression of MMP-9/-2 [166]. It has also been reported to possess suppressive effects on glioma cells (U87) proliferation via up-regulating the miR-16 expression and down-regulating the MMP-9 expression. As up-regulation of miR-16 can restrain tumor metastasis, therefore, osthole may has a potential as chemotherapeutic agent in future [160].



Osthole in combination with aconitine has capability to prohibit the migration of cancerous cells which is actually the result of alteration in the signaling pathway TGF- $\beta$ /Smad along with decreased expression of NF- $\kappa$ B and RANK [184]. Data by researchers recommend that osthole has competency to inhibit the invasion as well as migration in human colorectal cancer cells by down-regulation of the transcription factor snail, MMP-9, and the vimentin. In contrast, it also has a potential to up-regulate the epithelial protein E-cadherin [185]. It is suggested that wenshen zhuanggu formula (WSZG) is capable of inhibiting invasiveness of tumor cells by suppression of TGF- $\beta$ RI phosphorylation that can further hinder phosphatidylinositol 3-kinase/Akt signaling pathway and Smad2 [163, 186].



**Figure 3.** Diagrammatic representation of different molecular mechanisms responsible for the anticancer activity of osthole.

### 3.4.5. Micro RNA silencing

Micro RNAs are capable of modulating post transcription gene expression by hindering translation process or by enhancing the mRNA degradation [187, 188]. Micro RNA clusters

(miR-23a) are involved in regulating transforming growth factor- $\beta$ 1-induced EMT via targeting E-cadherin, thus, supporting tumorigenesis in cancer cells [7]. The study on profile of human cancer cells pinpointed a strong link among cancer metastasis and miRNA deregulation [189].

Osthole is capable of suppressing the miR-23a-3p expression as it has competency to suppress EMT-mediated invasive capability of AIPC by means of up-regulating the epigenetic EMT-related molecules;  $\beta$ -catenin, E-cad, and down-regulating the mesenchymal marker in prostate cancer cells DU145 and PC3 [168]. In glioma cells U87, osthole has been involved in the suppression of proliferation via elevating miR-16 expression and decreasing protein levels of MMP-9 [160]. Table 4 provides the comprehensive summary of compiled data depicting the targets of osthole in several cancers.

**Table 4.** The anticancer potential of osthole along with its molecular targets.

Types of cancer	Cell lines	EC <sub>50</sub> / Conc.	Molecular Targets	References
Breast	4T1, MDA-MB-231, MDA-MB 453, MCF-7,	10, 15, 20, 40, 60, 80, and 100 $\mu$ M	T $\beta$ RII $\downarrow$ , p-Akt $\downarrow$ , p-mTOR $\downarrow$ , TGF- $\beta$ -induced p-Smad2, p-Smad3 $\downarrow$ , c-Met $\downarrow$ , ERK $\downarrow$ , MMP-2 $\downarrow$ , Smad2 $\downarrow$ , Smad3 $\downarrow$ , Smad4 $\downarrow$ , Smad7 $\downarrow$ , NF- $\kappa$ B $\downarrow$ , RANK $\downarrow$ , TGF- $\beta$ 1 $\downarrow$	[39, 54, 59, 69, 80, 184, 190, 191]
Ovarian	A2780, OV2008	-	MMP-2/-9 $\downarrow$	[192]
Lung	NCI-H460, A549, CL1-5, H1299, SK-LU-1	50, 100, and 150 $\mu$ M	Bcl-2 $\downarrow$ , MMP-2/-9 $\downarrow$ , NF- $\kappa$ B $\downarrow$ , Cyclin B1 $\downarrow$ , p-Cdc2 $\downarrow$ , Bax $\uparrow$ , PI3K/Akt $\downarrow$ , I $\kappa$ B- $\alpha$ degradation $\downarrow$	[41, 54, 78, 166, 193]
Hepatocellular	HepG2, Hepa1-6, SMMC-7721	41, 82, 123, 164, and 205 $\mu$ M	NF- $\kappa$ B $\downarrow$ , cleaved caspase-3 $\uparrow$ , TNF $\uparrow$ , Bcl-2 $\uparrow$ , TRAF $\uparrow$ , CARD $\uparrow$ , CIDE $\uparrow$ , MMP-2/-9 $\downarrow$ , E-cadherin $\uparrow$ , beta-catenin $\uparrow$ , N-cadherin $\downarrow$ , vimentin $\downarrow$	[54, 157, 158]
Leukemia	L1210	-	-	[154]
Prostate	PC3, DU145, LNCaP	-	-	[154]
Gastric	MK-1	-	-	[45]
Colon	SW480, SW620	15 $\mu$ M	Cdc25 phosphatase $\downarrow$ , Cdc2/cyclin B $\downarrow$ , Bad $\uparrow$ , caspases-3/-7/-9 <sup>Act</sup>	[185]
Renal	ACHN, 786-O, Caki	-	E-cadherin $\uparrow$ , beta-catenin $\uparrow$ , vimentin $\downarrow$ , N-cadherin $\downarrow$ , Smad-3 $\downarrow$ , Twist-1 $\downarrow$ , Snail-1 $\downarrow$ , MMP-2/-9 $\downarrow$ , c-FLIP $\downarrow$	[194, 195]
Cholangiocarcinoma	HCCC-9810, RBE	159 $\mu$ M (48 h)	Bax $\uparrow$ , Bcl-2 $\uparrow$ , PARP $\uparrow$ ,	[175]

		(HCC-9810) 153 $\mu$ M (48 h) (RBE)	caspase-3, 9 $\uparrow$ , p-Akt $\downarrow$ , PI3K $\downarrow$	
Nasopharyngeal	NPC-039, NPC-BM	-	Bax $\uparrow$ , t-Bid $\uparrow$ , Bak $\uparrow$ , BimS $\uparrow$ , BimL $\uparrow$ , Fas $\uparrow$ , FADD $\uparrow$ , TNF-R1 $\uparrow$ , RIP $\uparrow$ , TNF-R2 $\uparrow$ , DcR2 $\uparrow$ , p- ERK1/2 $\uparrow$ , p-JNK1/2 $\uparrow$	[161]
Esophageal	KYSE150, KYSE410	198.45 $\mu$ M (24 h), 102.51 $\mu$ M (48 h) (KYSE150) 235.67 $\mu$ M (24 h) 114.02 $\mu$ M (48 h) (KYSE410)	Bcl-2 $\downarrow$ , Cdc2 $\downarrow$ , Cyclin B1 $\downarrow$ , PARP1 $\downarrow$ , Bax $\uparrow$ , cleaved PARP1 $\uparrow$ , caspase-3, 9 $\uparrow$ , p- AKT $\downarrow$ , PI3K $\downarrow$ , Survivin $\downarrow$	[162]

$\uparrow$ Up-regulation;  $\downarrow$ Down-regulation;  $\dashv$ Inhibition; MMP-2: Matrix metalloproteinase-2; HGF: Hepatocyte growth factor; ; TGF- $\beta$ 1: Transforming growth factor- $\beta$ 1; FASN: Fatty acid synthase; cellular FLICE-like inhibitory protein (c-FLIP)

### 3.5. Osthole and its other biological activities

Various *in vitro* studies have given evidences that osthole has ability to promote osteoblast differentiation and proliferation [70, 196-198], to abolish osteoclast formation and to inhibit bone resorption [82, 199], these properties support osthole as one of the promising candidates to cure osteoporosis. Total coumarins of *Fructus cnidii* caused effective inhibition of bone turnover and conversed the process of bone loss at earlier stage of menopause in ovariectomized rats [200]. Osthole supports osteoblast differentiation by Wnt/ $\beta$ -catenin activation with subsequent increase of Bmp2 expression [201].

Osthole has also shown protective effects against hepatitis by suppressing hepatitis B virus (HBV) surface antigens secretion in HuH-7 and MS-G2 cells via increasing glycosylation of HBsAg [202]. It has ability to prevent hepatitis induced by concanavalin A in the *in vivo* models [36]. Osthole has also been proved to be protective against hyperlipidemic condition [55] as well as in alcoholic fatty liver of animals [72].

Osthole has a potential to accelerate beta-oxidation of hepatic fatty acids, thus, contributing towards repression of lipid accumulation in liver suggesting that it could be effective to prevent atherosclerosis [33]. Osthole, a bioactive natural entity, ameliorated fatty liver by reducing mRNA expression of FAS and LDL receptor in mice [55], mitigated insulin resistance via enhancing the release of adiponectin through activating (PPAR $\alpha/\gamma$ ) signaling cascade [203]. Osthole has known to possess anti-fibrotic effects in HSC-T6 hepatic cells [204]. It has also been

proposed as preventive agent against isoprenaline-induced fibrosis as it up-regulates the expression of PPAR $\alpha$ / $\gamma$  with cessation of NF- $\kappa$ B signaling cascade in myocardial cells [52].

Additionally, osthole also possesses anti-diabetic properties. Various studies (*in vitro* and *in vivo*) investigations have revealed that osthole could mitigate hyperglycemia by activating PPAR $\alpha$ / $\gamma$ , and AMPK pathways [64, 205]. Osthole serves as vasorelaxant agent because of its antagonist effects on Ca<sup>2+</sup> channel via up-regulation of cyclic guanosine monophosphate (cGMP) levels in vascular smooth muscles [34]. It also exhibits relaxing effects on blood vessels as well as on other cells and tissues such as taenia coli, isolated guinea-pig ileum and trachea [100, 206], and on rabbit corpus cavernosum suggesting its effectiveness as relaxant agent [51]. Osthole is an anti-thrombotic agent that has potential to repress platelet coagulation by means of inhibiting thromboxane formation and breakdown of phosphoinositide [29, 207].

#### **4. Conclusions and future perspectives**

Natural products are torch bearers of specific advantages over traditional treatments being multi-targeted and less toxic, thus, providing a better version of remedy. Various naturally existing compounds have been declared as promising agents to suppress different cancer types in pre-clinical as well as clinical experimentation. Several reports have explored the role of osthole, one of bioactive constituent from variety of medicinal plants, as protective agent in several pathological conditions. Osthole has been known to inhibit cancer development and progression via modulating different signaling pathways. Although reported data acclaims that osthole possesses protective potential in various diseased conditions, however, further experimentation is required to evaluate pharmacokinetic profiles and molecular mechanism of osthole in depth as natural agent. In this way, a precise understanding of osthole can lead to better translation of its capabilities as anticancer agent in either pre-clinical or clinical perspectives in future.

#### **Acknowledgement**

We acknowledge this study towards the research grant from The Nagai Foundation Tokyo, Japan (NFT-R-2018), TWAS-COMSTECH Research Grant (No.\_17-180 RG/PHA/AS\_C) and NRPU Research Grants (8381/Punjab/NRPU/R&D/HEC/2017, 8382/Punjab/NRPU/R&D/HEC/2017). Moreover, we are highly obliged to HEC Pakistan for providing access to e-journals related to our study.

**Conflict of interest**

None

## References

1. Atanasov, A.G.; Waltenberger, B.; Pferschy-Wenzig, E.M.; Linder, T.; Wawrosch, C. Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnol Adv*, **2015**, 33(8), 1582-1614.
2. Li, Y.; Li, X.; Tip, P.; Zhang, L. Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. *Oncol Lett*, **2015**, 10(1), 263-267.
3. Ling, W.; Li, Y.; Jiang, W.; Sui, Y.; Zhao, H.L. Common Mechanism of Pathogenesis in Gastrointestinal Diseases Implied by Consistent Efficacy of Single Chinese Medicine Formula: A PRISMA-Compliant Systematic Review and Meta-Analysis. *Medicine (Baltimore)*, **2015**, 94(27), e1111.
4. Nabavi, S.M.; Marchese, A.; Izadi, M.; Curti, V.; Daglia, M. Plants belonging to the genus *Thymus* as antibacterial agents: from farm to pharmacy. *Food Chem*, **2015**, 173(339-347).
5. Rasul, A.; Millimouno, F.M.; Ali Eltayb, W.; Ali, M.; Li, J. Pinocembrin: a novel natural compound with versatile pharmacological and biological activities. *Biomed Res Int*, **2013**, 2013(379850).
6. Riaz, A.; Rasul, A.; Hussain, G.; Zahoor, M.K.; Jabeen, F. Astragalin: A Bioactive Phytochemical with Potential Therapeutic Activities. *Adv Pharmacol Sci*, **2018**, 2018(9794625).
7. Cao, M.; Seike, M.; Soeno, C.; Mizutani, H.; Kitamura, K. MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. *Int J Oncol*, **2012**, 41(3), 869-875.
8. Cotelle, N.; Bernier, J.L.; Catteau, J.P.; Pommery, J.; Wallet, J.C. Antioxidant properties of hydroxy-flavones. *Free Radic Biol Med*, **1996**, 20(1), 35-43.
9. Zheng, Y.; Lu, M.; Ma, L.; Zhang, S.; Qiu, M. Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response. *Urol Int*, **2013**, 91(3), 350-356.
10. Sharifi-Rad, M.; Varoni, E.M.; Salehi, B.; Sharifi-Rad, J.; Matthews, K.R. Plants of the Genus *Zingiber* as a Source of Bioactive Phytochemicals: From Tradition to Pharmacy. *Molecules*, **2017**, 22(12).

11. Sharifi-Rad, J.; Salehi, B.; Varoni, E.M.; Sharopov, F.; Yousaf, Z. Plants of the Melaleuca Genus as Antimicrobial Agents: From Farm to Pharmacy. *Phytother Res*, **2017**, 31(10), 1475-1494.
12. Salehi, B.; Ayatollahi, S.A.; Segura-Carretero, A.; Kobarfard, F.; Contreras, M.D.M. Bioactive chemical compounds in *Eremurus persicus* (Joub. & Spach) Boiss. essential oil and their health implications. *Cell Mol Biol (Noisy-le-grand)*, **2017**, 63(9), 1-7.
13. Sharifi-Rad, J.; Salehi, B.; Schnitzler, P.; Ayatollahi, S.A.; Kobarfard, F. Susceptibility of herpes simplex virus type 1 to monoterpenes thymol, carvacrol, p-cymene and essential oils of *Sinapis arvensis* L., *Lallemantia royleana* Benth. and *Pulicaria vulgaris* Gaertn. *Cell Mol Biol (Noisy-le-grand)*, **2017**, 63(8), 42-47.
14. Sharifi-Rad, J.; Salehi, B.; Stojanovic-Radic, Z.Z.; Fokou, P.V.T.; Sharifi-Rad, M. Medicinal plants used in the treatment of tuberculosis - Ethnobotanical and ethnopharmacological approaches. *Biotechnol Adv*, **2017**.
15. Halliwell, B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? *Lancet*, **1994**, 344(8924), 721-724.
16. Mitscher, L.A.; Telikepalli, H.; McGhee, E.; Shankel, D.M. Natural antimutagenic agents. *Mutat Res*, **1996**, 350(1), 143-152.
17. Owen, R.W.; Giacosa, A.; Hull, W.E.; Haubner, R.; Spiegelhalder, B. The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. *Eur J Cancer*, **2000**, 36(10), 1235-1247.
18. Sala, A.; Recio, M.; Giner, R.M.; Manez, S.; Tournier, H. Anti-inflammatory and antioxidant properties of *Helichrysum italicum*. *J Pharm Pharmacol*, **2002**, 54(3), 365-371.
19. Salehi, B.; Mishra, A.P.; Shukla, I.; Sharifi-Rad, M.; Contreras, M.D.M. Thymol, thyme, and other plant sources: Health and potential uses. *Phytother Res*, **2018**.
20. Sharifi-Rad, M.; Mnayer, D.; Morais-Braga, M.F.B.; Carneiro, J.N.P.; Bezerra, C.F. Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applications. *Phytother Res*, **2018**.
21. Sharifi-Rad, M.; Varoni, E.M.; Iriti, M.; Martorell, M.; Setzer, W.N. Carvacrol and human health: A comprehensive review. *Phytother Res*, **2018**.

22. Salehi, B.; Kumar, N.V.A.; Sener, B.; Sharifi-Rad, M.; Kilic, M. Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus. *Int J Mol Sci*, **2018**, 19(5).
23. Chang, C.I.; Hu, W.C.; Shen, C.P.; Hsu, B.D.; Lin, W.Y. 8-Alkylcoumarins from the fruits of *Cnidium monnieri* protect against hydrogen peroxide induced oxidative stress damage. *Int J Mol Sci*, **2014**, 15(3), 4608-4618.
24. Venugopala, K.N.; Rashmi, V.; Odhav, B. Review on natural coumarin lead compounds for their pharmacological activity. *Biomed Res Int*, **2013**, 2013(963248).
25. Okamoto, T.; Kobayashi, T.; Yoshida, S. Synthetic derivatives of osthole for the prevention of hepatitis. *Med Chem*, **2007**, 3(1), 35-44.
26. Tang, C.H.; Yang, R.S.; Chien, M.Y.; Chen, C.C.; Fu, W.M. Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. *Eur J Pharmacol*, **2008**, 579(1-3), 40-49.
27. Wu, C.; Sun, Z.; Guo, B.; Ye, Y.; Han, X. Osthole inhibits bone metastasis of breast cancer. *Oncotarget*, **2017**, 8(35), 58480-58493.
28. You, L.; Feng, S.; An, R.; Wang, X. Osthole: a promising lead compound for drug discovery from a traditional Chinese medicine (TCM). *Nat Prod Commun*, **2009**, 4(2), 297-302.
29. Ko, F.N.; Wu, T.S.; Liou, M.J.; Huang, T.F.; Teng, C.M. Inhibition of platelet thromboxane formation and phosphoinositides breakdown by osthole from *Angelica pubescens*. *Thromb Haemost*, **1989**, 62(3), 996-999.
30. Zhang, B.; Zhang, K.; Liu, Z.; Hao, F.; Wang, M. Secreted clusterin gene silencing enhances chemosensitivity of A549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. *Cell Physiol Biochem*, **2014**, 33(4), 1162-1175.
31. Matsuda, H.; Tomohiro, N.; Ido, Y.; Kubo, M. Anti-allergic effects of *Cnidii monnieri* fructus (dried fruits of *Cnidium monnieri*) and its major component, osthole. *Biol Pharm Bull*, **2002**, 25(6), 809-812.
32. Li, X.X.; Hara, I.; Matsumiya, T. Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; comparison to the effects of estradiol. *Biol Pharm Bull*, **2002**, 25(6), 738-742.



33. Ogawa, H.; Sasai, N.; Kamisako, T.; Baba, K. Effects of osthol on blood pressure and lipid metabolism in stroke-prone spontaneously hypertensive rats. *J Ethnopharmacol*, **2007**, 112(1), 26-31.
34. Ko, F.N.; Wu, T.S.; Liou, M.J.; Huang, T.F.; Teng, C.M. Vasorelaxation of rat thoracic aorta caused by osthole isolated from *Angelica pubescens*. *Eur J Pharmacol*, **1992**, 219(1), 29-34.
35. Shen, D.Y.; Chao, C.H.; Chan, H.H.; Huang, G.J.; Hwang, T.L. Bioactive constituents of *Clausena lansium* and a method for discrimination of aldose enantiomers. *Phytochemistry*, **2012**, 82(110-117).
36. Okamoto, T.; Yoshida, S.; Kobayashi, T.; Okabe, S. Inhibition of concanavalin A-induced mice hepatitis by coumarin derivatives. *Jpn J Pharmacol*, **2001**, 85(1), 95-97.
37. Zimecki, M.; Artym, J.; Cisowski, W.; Mazol, I.; Włodarczyk, M. Immunomodulatory and anti-inflammatory activity of selected osthole derivatives. *Z Naturforsch C*, **2009**, 64(5-6), 361-368.
38. Chou, S.Y.; Hsu, C.S.; Wang, K.T.; Wang, M.C.; Wang, C.C. Antitumor effects of Osthol from *Cnidium monnieri*: an in vitro and in vivo study. *Phytother Res*, **2007**, 21(3), 226-230.
39. Lin, V.C.; Chou, C.H.; Lin, Y.C.; Lin, J.N.; Yu, C.C. Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. *J Agric Food Chem*, **2010**, 58(8), 4786-4793.
40. Okamoto, T.; Kobayashi, T.; Yoshida, S. Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. *Curr Med Chem Anticancer Agents*, **2005**, 5(1), 47-51.
41. Xu, X.; Zhang, Y.; Qu, D.; Jiang, T.; Li, S. Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. *J Exp Clin Cancer Res*, **2011**, 30(33).
42. Shokoohinia, Y.; Jafari, F.; Mohammadi, Z.; Bazvandi, L.; Hosseinzadeh, L. Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review. *Nutrients*, **2018**, 10(1).

43. Zhang, Z.R.; Leung, W.N.; Cheung, H.Y.; Chan, C.W. Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine. *Evid Based Complement Alternat Med*, **2015**, 2015(919616).
44. Lee, Y.Y.; Lee, S.; Jin, J.L.; Yun-Choi, H.S. Platelet anti-aggregatory effects of coumarins from the roots of *Angelica genuflexa* and *A. gigas*. *Arch Pharm Res*, **2003**, 26(9), 723-726.
45. Fujioka, T.; Furumi, K.; Fujii, H.; Okabe, H.; Mihashi, K. Antiproliferative constituents from umbelliferae plants. V. A new furanocoumarin and faltarindiol furanocoumarin ethers from the root of *Angelica japonica*. *Chem Pharm Bull (Tokyo)*, **1999**, 47(1), 96-100.
46. Figueroa, M.; Rivero-Cruz, I.; Rivero-Cruz, B.; Bye, R.; Navarrete, A. Constituents, biological activities and quality control parameters of the crude extract and essential oil from *Arracacia toluensis* var. *multifida*. *J Ethnopharmacol*, **2007**, 113(1), 125-131.
47. Resch, M.; Steigel, A.; Chen, Z.L.; Bauer, R. 5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from *Atractylodes lancea*. *J Nat Prod*, **1998**, 61(3), 347-350.
48. Siskos, E.P.; Mazomenos, B.E.; Konstantopoulou, M.A. Isolation and identification of insecticidal components from *Citrus aurantium* fruit peel extract. *J Agric Food Chem*, **2008**, 56(14), 5577-5581.
49. Basnet, P.; Yasuda, I.; Kumagai, N.; Tohda, C.; Nojima, H. Inhibition of itch-scratch response by fruits of *Cnidium monnieri* in mice. *Biol Pharm Bull*, **2001**, 24(9), 1012-1015.
50. Chen, D.; Wang, J.; Jiang, Y.; Zhou, T.; Fan, G. Separation and determination of coumarins in *Fructus cnidii* extracts by pressurized capillary electrochromatography using a packed column with a monolithic outlet frit. *J Pharm Biomed Anal*, **2009**, 50(5), 695-702.
51. Chen, J.; Chiou, W.F.; Chen, C.C.; Chen, C.F. Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro. *J Urol*, **2000**, 163(6), 1975-1980.
52. Chen, R.; Xue, J.; Xie, M.L. Reduction of isoprenaline-induced myocardial TGF-beta1 expression and fibrosis in osthole-treated mice. *Toxicol Appl Pharmacol*, **2011**, 256(2), 168-173.

53. Chen, T.; Liu, W.; Chao, X.; Qu, Y.; Zhang, L. Neuroprotective effect of osthole against oxygen and glucose deprivation in rat cortical neurons: involvement of mitogen-activated protein kinase pathway. *Neuroscience*, **2011**, 183(203-211).
54. Dien, P.H.; Nhan, N.T.; Le Thuy, H.T.; Quang, D.N. Main constituents from the seeds of Vietnamese *Cnidium monnieri* and cytotoxic activity. *Nat Prod Res*, **2012**, 26(22), 2107-2111.
55. Du, R.; Xue, J.; Wang, H.B.; Zhang, Y.; Xie, M.L. Osthole ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression. *Eur J Pharmacol*, **2011**, 666(1-3), 183-188.
56. Chen, X.J.; Zhang, B.; Hou, S.J.; Shi, Y.; Xu, D.Q. Osthole improves acute lung injury in mice by up-regulating Nrf-2/thioredoxin 1. *Respir Physiol Neurobiol*, **2013**, 188(2), 214-222.
57. Chiou, W.F.; Huang, Y.L.; Chen, C.F.; Chen, C.C. Vasorelaxing effect of coumarins from *Cnidium monnieri* on rabbit corpus cavernosum. *Planta Med*, **2001**, 67(3), 282-284.
58. Gao, F.; Hu, Y.; Ye, X.; Li, J.; Chen, Z. Optimal extraction and fingerprint analysis of *Cnidii fructus* by accelerated solvent extraction and high performance liquid chromatographic analysis with photodiode array and mass spectrometry detections. *Food Chem*, **2013**, 141(3), 1962-1971.
59. Han, X.H.; Ye, Y.Y.; Guo, B.F.; Liu, S. [Effects of platycodin D in combination with different active ingredients of Chinese herbs on proliferation and invasion of 4T1 and MDA-MB-231 breast cancer cell lines]. *Zhong Xi Yi Jie He Xue Bao*, **2012**, 10(1), 67-75.
60. Hou, X.; Zhou, M.; Jiang, Q.; Wang, S.; He, L. A vascular smooth muscle/cell membrane chromatography-offline-gas chromatography/mass spectrometry method for recognition, separation and identification of active components from traditional Chinese medicines. *J Chromatogr A*, **2009**, 1216(42), 7081-7087.
61. Huang, W.J.; Chen, C.C.; Chao, S.W.; Yu, C.C.; Yang, C.Y. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. *Eur J Med Chem*, **2011**, 46(9), 4042-4049.
62. Jiang, T.F.; Lv, Z.H.; Wang, Y.H.; Yue, M.E. On-line concentration by field-enhanced sample injection with reverse migrating micelles in micellar electrokinetic capillary

- chromatography for the analysis of coumarins from traditional Chinese medicine and human serum. *Biomed Chromatogr*, **2010**, 24(6), 581-587.
63. Li, F.; Gong, Q.; Wang, L.; Shi, J. Osthole attenuates focal inflammatory reaction following permanent middle cerebral artery occlusion in rats. *Biol Pharm Bull*, **2012**, 35(10), 1686-1690.
  64. Liang, H.J.; Suk, F.M.; Wang, C.K.; Hung, L.F.; Liu, D.Z. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. *Chem Biol Interact*, **2009**, 181(3), 309-315.
  65. Lin, L.W.; Kuo, Y.H.; Hseu, Y.C.; Tsai, C.W.; Hsieh, M.T. Osthole Improves Spatial Memory Deficits in Rats via Hippocampal alpha 1-Adrenergic and D 1 /D 2 Receptors. *Evid Based Complement Alternat Med*, **2013**, 2013(273682).
  66. Lin, T.Y.; Lu, C.W.; Huang, W.J.; Wang, S.J. Involvement of the cGMP pathway in the osthole-facilitated glutamate release in rat hippocampal nerve endings. *Synapse*, **2012**, 66(3), 232-239.
  67. Liu, G.L.; Hao, B.; Liu, S.P.; Wang, G.X. Synthesis and anthelmintic activity of osthol analogs against *Dactylogyrus intermedius* in goldfish. *Eur J Med Chem*, **2012**, 54(582-590).
  68. Liu, W.B.; Zhou, J.; Qu, Y.; Li, X.; Lu, C.T. Neuroprotective effect of osthole on MPP<sup>+</sup>-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. *Neurochem Int*, **2010**, 57(3), 206-215.
  69. Yang, D.; Gu, T.; Wang, T.; Tang, Q.; Ma, C. Effects of osthole on migration and invasion in breast cancer cells. *Biosci Biotechnol Biochem*, **2010**, 74(7), 1430-1434.
  70. Ming, L.G.; Zhou, J.; Cheng, G.Z.; Ma, H.P.; Chen, K.M. Osthol, a coumarin isolated from common cnidium fruit, enhances the differentiation and maturation of osteoblasts in vitro. *Pharmacology*, **2011**, 88(1-2), 33-43.
  71. Nakamura, T.; Kodama, N.; Arai, Y.; Kumamoto, T.; Higuchi, Y. Inhibitory effect of oxycoumarins isolated from the Thai medicinal plant *Clausena guillauminii* on the inflammation mediators, iNOS, TNF-alpha, and COX-2 expression in mouse macrophage RAW 264.7. *J Nat Med*, **2009**, 63(1), 21-27.

72. Song, F.; Xie, M.L.; Zhu, L.J.; Zhang, K.P.; Xue, J. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals. *World J Gastroenterol*, **2006**, 12(27), 4359-4363.
73. Sun, W.J.; Sha, Z.F.; Gao, H. [Determination of osthol and imperatorin in *Cnidium monnieri* (L.) cuss by fluorometry TLC scanning]. *Yao Xue Xue Bao*, **1990**, 25(7), 530-533.
74. Tsai, T.H.; Tsai, T.R.; Chen, C.C.; Chen, C.F. Pharmacokinetics of osthole in rat plasma using high-performance liquid chromatography. *J Pharm Biomed Anal*, **1996**, 14(6), 749-753.
75. Wang, G.; Zhou, Z.; Cheng, C.; Yao, J.; Yang, Z. Osthol and isopimpinellin from *Fructus cnidii* for the control of *Dactylogyrus intermedius* in *Carassius auratus*. *Vet Parasitol*, **2008**, 158(1-2), 144-151.
76. Wang, Z.C.; Feng, D.Q.; Ke, C.H. Coumarins from the Herb *Cnidium monnieri* and chemically modified derivatives as antifoulants against *Balanus albicostatus* and *Bugula neritina* larvae. *Int J Mol Sci*, **2013**, 14(1), 1197-1206.
77. Wu, C.R.; Lin, L.W.; Hsieh, C.L.; Wang, W.H.; Lin, Y.T. Petroleum ether extract of *Cnidium monnieri* ameliorated scopolamine-induced amnesia through adrenal gland-mediated mechanism in male rats. *J Ethnopharmacol*, **2008**, 117(3), 403-407.
78. Xu, X.M.; Zhang, Y.; Qu, D.; Feng, X.W.; Chen, Y. Osthole suppresses migration and invasion of A549 human lung cancer cells through inhibition of matrix metalloproteinase-2 and matrix metalloproteinase-9 in vitro. *Mol Med Rep*, **2012**, 6(5), 1018-1022.
79. Yang, Y.C.; Chen, C.N.; Wu, C.I.; Huang, W.J.; Kuo, T.Y. NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. *Evid Based Complement Alternat Med*, **2013**, 2013(514908).
80. Ye, Y.; Han, X.; Guo, B.; Sun, Z.; Liu, S. Combination treatment with platycodin D and osthole inhibits cell proliferation and invasion in mammary carcinoma cell lines. *Environ Toxicol Pharmacol*, **2013**, 36(1), 115-124.

81. Zaugg, J.; Eickmeier, E.; Rueda, D.C.; Hering, S.; Hamburger, M. HPLC-based activity profiling of *Angelica pubescens* roots for new positive GABAA receptor modulators in *Xenopus* oocytes. *Fitoterapia*, **2011**, 82(3), 434-440.
82. Zhang, Q.; Qin, L.; He, W.; Van Puyvelde, L.; Maes, D. Coumarins from *Cnidium monnieri* and their antiosteoporotic activity. *Planta Med*, **2007**, 73(1), 13-19.
83. Zhou, F.; Zhong, W.; Xue, J.; Gu, Z.L.; Xie, M.L. Reduction of rat cardiac hypertrophy by osthole is related to regulation of cardiac oxidative stress and lipid metabolism. *Lipids*, **2012**, 47(10), 987-994.
84. Shen, D.Y.; Chan, Y.Y.; Hwang, T.L.; Juang, S.H.; Huang, S.C. Constituents of the roots of *Clausena lansium* and their potential anti-inflammatory activity. *J Nat Prod*, **2014**, 77(5), 1215-1223.
85. Li, Y.; Liu, X.L.; Cai, Z.G.; Zhang, S.X. LC-ESI-MS/MS analysis and pharmacokinetics of jolkinolide B, a potential antitumor active component isolated from *Euphorbia fischeriana*, in rat plasma. *Biomed Chromatogr*, **2014**, 28(2), 193-196.
86. Jimenez, B.; Grande, M.C.; Anaya, J.; Torres, P.; Grande, M. Coumarins from *Ferulago capillaris* and *F. brachyloba*. *Phytochemistry*, **2000**, 53(8), 1025-1031.
87. Sheng, L.; Wu, C.Y.; Chen, X.F. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*, **2011**, 31(5), 684-689.
88. Liu, Y.Y.; Zhang, C.; Li, L.; Xiao, Y.Q. [Studies on chemical constituents in roots of *Heracleum rapula*]. *Zhongguo Zhong Yao Za Zhi*, **2006**, 31(4), 309-311.
89. Anand Solomon, K.; Rajan, S.S.; Gopalakrishnan, G.; Kashinath, V.; Santhana Krishnan, V.P. 8-(2-bromo-3-methoxy-3-methylbutyl)-7-methoxycoumarin. *Acta Crystallogr C*, **2003**, 59(Pt 1), O40-41.
90. Shi, J.; Fu, Q.; Chen, W.; Yang, H.P.; Liu, J. Comparative study of pharmacokinetics and tissue distribution of osthole in rats after oral administration of pure osthole and *Libanotis buchtormensis* supercritical extract. *J Ethnopharmacol*, **2013**, 145(1), 25-31.
91. Cisowski, W.; Sawicka, U.; Mardarowicz, M.; Asztemborska, M.; Luczkiewicz, M. Essential oil from herb and rhizome of *Peucedanum ostruthium* (L. Koch.) ex DC. *Z Naturforsch C*, **2001**, 56(11-12), 930-932.

92. Vogl, S.; Zehl, M.; Picker, P.; Urban, E.; Wawrosch, C. Identification and quantification of coumarins in *Peucedanum ostruthium* (L.) Koch by HPLC-DAD and HPLC-DAD-MS. *J Agric Food Chem*, **2011**, 59(9), 4371-4377.
93. Sadraei, H.; Shokoohinia, Y.; Sajjadi, S.E.; Ghadirian, B. Antispasmodic effect of osthole and *Prangos ferulacea* extract on rat uterus smooth muscle motility. *Res Pharm Sci*, **2012**, 7(3), 141-149.
94. Sadraei, H.; Shokoohinia, Y.; Sajjadi, S.E.; Mozafari, M. Antispasmodic effects of *Prangos ferulacea* acetone extract and its main component osthole on ileum contraction. *Res Pharm Sci*, **2013**, 8(2), 137-144.
95. Chang, Y.X.; Zhang, Q.H.; Li, J.; Zhang, L.; Guo, X.R. Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of *Radix Angelicae Pubescentis* extract. *J Pharm Biomed Anal*, **2013**, 77(71-75).
96. Chen, Y.F.; Tsai, H.Y.; Wu, T.S. Anti-inflammatory and analgesic activities from roots of *Angelica pubescens*. *Planta Med*, **1995**, 61(1), 2-8.
97. Li, R.Z.; He, Y.Q.; Chiao, M.; Xu, Y.; Zhang, Q.B. [Studies of the active constituents of the Chinese drug "duhuo" *Angelica pubescens*]. *Yao Xue Xue Bao*, **1989**, 24(7), 546-551.
98. Liu, J.H.; Zschocke, S.; Reininger, E.; Bauer, R. Inhibitory effects of *Angelica pubescens* f. *biserrata* on 5-lipoxygenase and cyclooxygenase. *Planta Med*, **1998**, 64(6), 525-529.
99. Luo, Q.; Wang, C.P.; Li, J.; Ma, W.F.; Bai, Y. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration. *J Ethnopharmacol*, **2013**, 150(1), 175-180.
100. Teng, C.M.; Lin, C.H.; Ko, F.N.; Wu, T.S.; Huang, T.F. The relaxant action of osthole isolated from *Angelica pubescens* in guinea-pig trachea. *Naunyn Schmiedeberg's Arch Pharmacol*, **1994**, 349(2), 202-208.
101. Wang, K.Y.; Yao, L.; Du, Y.H.; Xie, J.B.; Huang, J.L. Anthelmintic activity of the crude extracts, fractions, and osthole from *Radix angelicae pubescentis* against *Dactylogyrus intermedius* in goldfish (*Carassius auratus*) in vivo. *Parasitol Res*, **2011**, 108(1), 195-200.

102. Yang, X.W.; Guo, Q.M.; Wang, Y. [Absorption and transport of 6 coumarins isolated from the roots of *Angelica pubescens* f. *biserrata* in human Caco-2 cell monolayer model]. *Zhong Xi Yi Jie He Xue Bao*, **2008**, 6(4), 392-398.
103. Yao, L.; Lu, P.; Li, Y.; Yang, L.; Feng, H. Osthole relaxes pulmonary arteries through endothelial phosphatidylinositol 3-kinase/Akt-eNOS-NO signaling pathway in rats. *Eur J Pharmacol*, **2013**, 699(1-3), 23-32.
104. Huo, L.; Jiang, Z.; Lei, M.; Wang, X.; Guo, X. Simultaneous quantification of Kirenol and ent-16beta,17-dihydroxy-kauran-19-oic acid from *Herba Siegesbeckiae* in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. *J Chromatogr B Analyt Technol Biomed Life Sci*, **2013**, 937(18-24).
105. Tosun, A.; Akkol, E.K.; Yesilada, E. Anti-inflammatory and antinociceptive activity of coumarins from *Seseli gummiferum* subsp. *corymbosum* (Apiaceae). *Z Naturforsch C*, **2009**, 64(1-2), 56-62.
106. Sharma, R.K.; Negi, D.S.; Gibbons, S.; Otsuka, H. Chemical and antibacterial constituents of *Skimmia anquetelia*. *Planta Med*, **2008**, 74(2), 175-177.
107. Rao, G.X.; Gao, Y.L.; Lin, Y.P.; Xiao, Y.L.; Li, S.H. Chemical constituents of *Selinum cryptotaenium*. *J Asian Nat Prod Res*, **2006**, 8(3), 273-275.
108. Nathan, C.; Ding, A. Nonresolving inflammation. *Cell*, **2010**, 140(6), 871-882.
109. Shi, Y.; Zhang, B.; Chen, X.J.; Xu, D.Q.; Wang, Y.X. Osthole protects lipopolysaccharide-induced acute lung injury in mice by preventing down-regulation of angiotensin-converting enzyme 2. *Eur J Pharm Sci*, **2013**, 48(4-5), 819-824.
110. Liao, P.C.; Chien, S.C.; Ho, C.L.; Wang, E.I.; Lee, S.C. Osthole regulates inflammatory mediator expression through modulating NF-kappaB, mitogen-activated protein kinases, protein kinase C, and reactive oxygen species. *J Agric Food Chem*, **2010**, 58(19), 10445-10451.
111. Chao, X.; Zhou, J.; Chen, T.; Liu, W.; Dong, W. Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlusion in rats. *Brain Res*, **2010**, 1363(206-211).



112. Hua, K.F.; Yang, S.M.; Kao, T.Y.; Chang, J.M.; Chen, H.L. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and NF-kappaB/NLRP3 pathway. *PLoS One*, **2013**, 8(10), e77794.
113. Xie, D.Q.; Sun, G.Y.; Zhang, X.G.; Gan, H. Osthole Preconditioning Protects Rats Against Renal Ischemia-Reperfusion Injury. *Transplant Proc*, **2015**, 47(6), 1620-1626.
114. Yu, H.P.; Liu, F.C.; Tsai, Y.F.; Hwang, T.L. Osthole attenuates hepatic injury in a rodent model of trauma-hemorrhage. *PLoS One*, **2013**, 8(6), e65916.
115. Li, Z.; Ji, H.; Song, X.; Hu, J.; Han, N. Osthole attenuates the development of carrageenan-induced lung inflammation in rats. *Int Immunopharmacol*, **2014**, 20(1), 33-36.
116. Sun, F.; Xie, M.L.; Zhu, L.J.; Xue, J.; Gu, Z.L. Inhibitory effect of osthole on alcohol-induced fatty liver in mice. *Dig Liver Dis*, **2009**, 41(2), 127-133.
117. Huang, W.C.; Liao, P.C.; Huang, C.H.; Hu, S.; Huang, S.C. Osthole attenuates lipid accumulation, regulates the expression of inflammatory mediators, and increases antioxidants in FL83B cells. *Biomed Pharmacother*, **2017**, 91(78-87).
118. Huang, T.; Dong, Z. Osthole protects against inflammation in a rat model of chronic kidney failure via suppression of nuclear factor-kappaB, transforming growth factor-beta1 and activation of phosphoinositide 3-kinase/protein kinase B/nuclear factor (erythroid-derived 2)-like 2 signaling. *Mol Med Rep*, **2017**, 16(4), 4915-4921.
119. Li, Y.; Li, Y.; Shi, F.; Wang, L.; Li, L. Osthole attenuates right ventricular remodeling via decreased myocardial apoptosis and inflammation in monocrotaline-induced rats. *Eur J Pharmacol*, **2018**, 818(525-533).
120. Xu, R.; Liu, Z.; Hou, J.; Huang, T.; Yang, M. Osthole improves collagen-induced arthritis in a rat model through inhibiting inflammation and cellular stress. *Cell Mol Biol Lett*, **2018**, 23(19).
121. Bao, Y.; Meng, X.; Liu, F.; Wang, F.; Yang, J. Protective effects of osthole against inflammation induced by lipopolysaccharide in BV2 cells. *Mol Med Rep*, **2018**, 17(3), 4561-4566.
122. Cai, Y.; Sun, W.; Zhang, X.X.; Lin, Y.D.; Chen, H. Osthole prevents acetaminophen-induced liver injury in mice. *Acta Pharmacol Sin*, **2018**, 39(1), 74-84.

123. Zhou, W.B.; Zhang, X.X.; Cai, Y.; Sun, W.; Li, H. Osthole prevents tamoxifen-induced liver injury in mice. *Acta Pharmacol Sin*, **2019**, 40(5), 608-619.
124. Wang, X.Y.; Dong, W.P.; Bi, S.H.; Pan, Z.G.; Yu, H. Protective effects of osthole against myocardial ischemia/reperfusion injury in rats. *Int J Mol Med*, **2013**, 32(2), 365-372.
125. He, Q.L.; Chen, Y.; Qin, J.; Mo, S.L.; Wei, M. Osthole, a herbal compound, alleviates nucleus pulposus-evoked nociceptive responses through the suppression of overexpression of acid-sensing ion channel 3 (ASIC3) in rat dorsal root ganglion. *Med Sci Monit*, **2012**, 18(6), BR229-236.
126. Chiu, P.R.; Lee, W.T.; Chu, Y.T.; Lee, M.S.; Jong, Y.J. Effect of the Chinese herb extract osthonol on IL-4-induced eotaxin expression in BEAS-2B cells. *Pediatr Neonatol*, **2008**, 49(4), 135-140.
127. Wei, M.; Zhang, J.J.; He, Q.L.; Wang, L.; Ren, Z.H. [Effects and mechanisms of osthole on sciatica induced by lumbar disc herniation]. *Zhong Yao Cai*, **2011**, 34(5), 746-750.
128. Liu, J.; Zhang, W.; Zhou, L.; Wang, X.; Lian, Q. Anti-inflammatory effect and mechanism of osthole in rats. *Zhong Yao Cai*, **2005**, 28(11), 1002-1006.
129. Zhao, X.; Wang, F.; Zhou, R.; Zhu, Z.; Xie, M. PPARalpha/gamma antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatic rats. *Inflammopharmacology*, **2018**, 26(2), 425-433.
130. Ji, H.J.; Hu, J.F.; Wang, Y.H.; Chen, X.Y.; Zhou, R. Osthole improves chronic cerebral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus. *Eur J Pharmacol*, **2010**, 636(1-3), 96-101.
131. Zhou, Y.F.; Li, L.; Feng, F.; Yuan, H.; Gao, D.K. Osthole attenuates spinal cord ischemia-reperfusion injury through mitochondrial biogenesis-independent inhibition of mitochondrial dysfunction in rats. *J Surg Res*, **2013**, 185(2), 805-814.
132. He, Y.; Qu, S.; Wang, J.; He, X.; Lin, W. Neuroprotective effects of osthole pretreatment against traumatic brain injury in rats. *Brain Res*, **2012**, 1433(127-136).
133. Yao, Y.; Gao, Z.; Liang, W.; Kong, L.; Jiao, Y. Osthole promotes neuronal differentiation and inhibits apoptosis via Wnt/beta-catenin signaling in an Alzheimer's disease model. *Toxicol Appl Pharmacol*, **2015**, 289(3), 474-481.
134. Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev*, **2014**, 94(3), 909-950.

135. Sinha, N.; Dabla, P.K. Oxidative stress and antioxidants in hypertension-a current review. *Curr Hypertens Rev*, **2015**, 11(2), 132-142.
136. Wu, L.; Wang, X.; Xu, W.; Farzaneh, F.; Xu, R. The structure and pharmacological functions of coumarins and their derivatives. *Curr Med Chem*, **2009**, 16(32), 4236-4260.
137. Tsai, Y.F.; Yu, H.P.; Chung, P.J.; Leu, Y.L.; Kuo, L.M. Osthole attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of phosphodiesterase 4. *Free Radic Biol Med*, **2015**, 89(387-400).
138. Yang, S.M.; Chan, Y.L.; Hua, K.F.; Chang, J.M.; Chen, H.L. Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-kappaB-mediated COX-2 expression and apoptosis. *Free Radic Biol Med*, **2014**, 73(260-269).
139. Zheng, Y.; Lu, M.; Ma, L.; Zhang, S.; Qiu, M. Osthole ameliorates renal ischemia-reperfusion injury in rats. *J Surg Res*, **2013**, 183(1), 347-354.
140. Zhang, Z.; Pan, C.; Wang, H.Z.; Li, Y.X. Protective effects of osthole on intestinal ischemia-reperfusion injury in mice. *Exp Clin Transplant*, **2014**, 12(3), 246-252.
141. Dong, W.; Zhang, Z.; Liu, Z.; Liu, H.; Wang, X. Protective effects of osthole, a natural derivative of coumarin, against intestinal ischemia-reperfusion injury in mice. *Int J Mol Med*, **2013**, 31(6), 1367-1374.
142. Hu, Y.; Wen, Q.; Liang, W.; Kang, T.; Ren, L. Osthole reverses beta-amyloid peptide cytotoxicity on neural cells by enhancing cyclic AMP response element-binding protein phosphorylation. *Biol Pharm Bull*, **2013**, 36(12), 1950-1958.
143. Shen, L.X.; Jin, L.Q.; Zhang, D.S.; Xue, G.P. [Effect of osthole on memory impairment of mice in AlCl<sub>3</sub>-induced acute senile model]. *Yao Xue Xue Bao*, **2002**, 37(3), 178-180.
144. Du, R.; Meng, Z.Y.; Wang, J.L.; Wang, Y.L. Efficacy of Osthole in Management of Hypoperfused Retina. *J Ophthalmol*, **2018**, 2018(6178347).
145. Yao, Y.; Zhao, X.; Xin, J.; Wu, Y.; Li, H. Coumarins improved type 2 diabetes induced by high-fat diet and streptozotocin in mice via antioxidation. *Can J Physiol Pharmacol*, **2018**, 1-7.
146. Khairy, H.; Saleh, H.; Badr, A.M.; Marie, M.S. Therapeutic efficacy of osthole against dinitrobenzene sulphonic acid induced-colitis in rats. *Biomed Pharmacother*, **2018**, 100(42-51).

147. Wyllie, A.H. "Where, O death, is thy sting?" A brief review of apoptosis biology. *Mol Neurobiol*, **2010**, 42(1), 4-9.
148. Green, D.R.; Llambi, F. Cell Death Signaling. *Cold Spring Harb Perspect Biol*, **2015**, 7(12).
149. Duprez, L.; Wirawan, E.; Vanden Berghe, T.; Vandenabeele, P. Major cell death pathways at a glance. *Microbes Infect*, **2009**, 11(13), 1050-1062.
150. Whelan, R.S.; Kaplinskiy, V.; Kitsis, R.N. Cell death in the pathogenesis of heart disease: mechanisms and significance. *Annu Rev Physiol*, **2010**, 72(19-44).
151. Rasul, A.; Yu, B.; Khan, M.; Zhang, K.; Iqbal, F. Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. *Int J Oncol*, **2012**, 40(4), 1153-1161.
152. Zhou, Z.W.; Liu, P.X. [Progress in study of chemical constituents and anti-tumor activities of *Cnidium monnieri*]. *Zhongguo Zhong Yao Za Zhi*, **2005**, 30(17), 1309-1313.
153. Kawaii, S.; Tomono, Y.; Ogawa, K.; Sugiura, M.; Yano, M. Antiproliferative effect of isopentenylated coumarins on several cancer cell lines. *Anticancer Res*, **2001**, 21(3B), 1905-1911.
154. Riviere, C.; Goossens, L.; Pommery, N.; Fourneau, C.; Delelis, A. Antiproliferative effects of isopentenylated coumarins isolated from *Phellolophium madagascariense* Baker. *Nat Prod Res*, **2006**, 20(10), 909-916.
155. Yang, L.L.; Wang, M.C.; Chen, L.G.; Wang, C.C. Cytotoxic activity of coumarins from the fruits of *Cnidium monnieri* on leukemia cell lines. *Planta Med*, **2003**, 69(12), 1091-1095.
156. Feng, H.; Lu, J.J.; Wang, Y.; Pei, L.; Chen, X. Osthole inhibited TGF beta-induced epithelial-mesenchymal transition (EMT) by suppressing NF-kappaB mediated Snail activation in lung cancer A549 cells. *Cell Adh Migr*, **2017**, 11(5-6), 464-475.
157. Zhang, L.; Jiang, G.; Yao, F.; He, Y.; Liang, G. Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. *PLoS One*, **2012**, 7(5), e37865.
158. Lin, Z.K.; Liu, J.; Jiang, G.Q.; Tan, G.; Gong, P. Osthole inhibits the tumorigenesis of hepatocellular carcinoma cells. *Oncol Rep*, **2017**, 37(3), 1611-1618.

159. Jarzab, A.; Grabarska, A.; Kielbus, M.; Jeleniewicz, W.; Dmoszynska-Graniczka, M. Osthole induces apoptosis, suppresses cell-cycle progression and proliferation of cancer cells. *Anticancer Res*, **2014**, 34(11), 6473-6480.
160. Lin, K.; Gao, Z.; Shang, B.; Sui, S.; Fu, Q. Osthole suppresses the proliferation and accelerates the apoptosis of human glioma cells via the upregulation of microRNA-16 and downregulation of MMP-9. *Mol Med Rep*, **2015**, 12(3), 4592-4597.
161. Liu, P.Y.; Chang, D.C.; Lo, Y.S.; Hsi, Y.T.; Lin, C.C. Osthole induces human nasopharyngeal cancer cells apoptosis through Fas-Fas ligand and mitochondrial pathway. *Environ Toxicol*, **2018**, 33(4), 446-453.
162. Zhu, X.; Li, Z.; Li, T.; Long, F.; Lv, Y. Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma. *Biomed Pharmacother*, **2018**, 102(502-509).
163. Xu, X.; Liu, X.; Zhang, Y. Osthole inhibits gastric cancer cell proliferation through regulation of PI3K/AKT. *PLoS One*, **2018**, 13(3), e0193449.
164. Huang, S.M.; Tsai, C.F.; Chen, D.R.; Wang, M.Y.; Yeh, W.L. p53 is a key regulator for osthole-triggered cancer pathogenesis. *Biomed Res Int*, **2014**, 2014(175247).
165. Ding, Y.; Lu, X.; Hu, X.; Ma, J.; Ding, H. Osthole inhibits proliferation and induces apoptosis in human osteosarcoma cells. *Int J Clin Pharmacol Ther*, **2014**, 52(2), 112-117.
166. Kao, S.J.; Su, J.L.; Chen, C.K.; Yu, M.C.; Bai, K.J. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. *Toxicol Appl Pharmacol*, **2012**, 261(1), 105-115.
167. Lin, Y.C.; Lin, J.C.; Hung, C.M.; Chen, Y.; Liu, L.C. Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells. *J Agric Food Chem*, **2014**, 62(22), 5061-5071.
168. Wen, Y.C.; Lee, W.J.; Tan, P.; Yang, S.F.; Hsiao, M. By inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer. *Oncotarget*, **2015**, 6(25), 21120-21136.
169. Pai, J.T.; Hsu, C.Y.; Hua, K.T.; Yu, S.Y.; Huang, C.Y. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. *Molecules*, **2015**, 20(5), 8000-8019.

170. Wang, L.; Peng, Y.; Shi, K.; Wang, H.; Lu, J. Osthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis. *J Biomed Res*, **2015**, 29(2), 132-138.
171. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov*, **2009**, 8(8), 627-644.
172. El-Masry, O.S.; Al-Sakkaf, K.; Brown, B.L.; Dobson, P.R. Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation. *Oncol Rep*, **2015**, 34(4), 1675-1680.
173. Chen, T.J.; Zhou, Y.F.; Ning, J.J.; Yang, T.; Ren, H. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway. *Cell Physiol Biochem*, **2015**, 36(3), 893-906.
174. Ding, D.; Wei, S.; Song, Y.; Li, L.; Du, G. Osthole exhibits anti-cancer property in rat glioma cells through inhibiting PI3K/Akt and MAPK signaling pathways. *Cell Physiol Biochem*, **2013**, 32(6), 1751-1760.
175. Zhu, X.; Song, X.; Xie, K.; Zhang, X.; He, W. Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma. *Int J Mol Med*, **2017**, 40(4), 1143-1151.
176. Vander Broek, R.; Snow, G.E.; Chen, Z.; Van Waes, C. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB signaling. *Oral Oncol*, **2014**, 50(10), 930-941.
177. Che, Y.; Li, J.; Li, Z.; Li, J.; Wang, S. Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NFkappaB signaling. *Oncol Rep*, **2018**, 40(2), 737-747.
178. Selivanova, G. Therapeutic targeting of p53 by small molecules. *Semin Cancer Biol*, **2010**, 20(1), 46-56.
179. Feldser, D.M.; Kostova, K.K.; Winslow, M.M.; Taylor, S.E.; Cashman, C. Stage-specific sensitivity to p53 restoration during lung cancer progression. *Nature*, **2010**, 468(7323), 572-575.

180. Junttila, M.R.; Karnezis, A.N.; Garcia, D.; Madriles, F.; Kortlever, R.M. Selective activation of p53-mediated tumour suppression in high-grade tumours. *Nature*, **2010**, 468(7323), 567-571.
181. Chao, X.; Zhou, X.; Zheng, G.; Dong, C.; Zhang, W. Osthole induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. *Pharm Biol*, **2014**, 52(5), 544-550.
182. Wan, L.; Pantel, K.; Kang, Y. Tumor metastasis: moving new biological insights into the clinic. *Nat Med*, **2013**, 19(11), 1450-1464.
183. Steeg, P.S. Targeting metastasis. *Nat Rev Cancer*, **2016**, 16(4), 201-218.
184. Guo, B.F.; Liu, S.; Ye, Y.Y.; Han, X.H. [Inhibitory effects of osthole, psoralen and aconitine on invasive activities of breast cancer MDA-MB-231BO cell line and the mechanisms]. *Zhong Xi Yi Jie He Xue Bao*, **2011**, 9(10), 1110-1117.
185. Liu, L.Y.; Huang, W.J.; Ho, F.M.; Lin, R.J.; Lin, S.Y. N-Hydroxycinnamide derivatives of osthole inhibit cell migration and invasion by suppressing Smad2 and Akt pathways in human colorectal adenocarcinoma cells. *Chem Biol Interact*, **2014**, 217(1-8).
186. Han, X.H.; Wang, C.L.; Xie, Y.; Ma, J.; Zhang, X.H. Anti-metastatic effect and mechanisms of Wenshen Zhuanggu Formula in human breast cancer cells. *J Ethnopharmacol*, **2015**, 162(39-46).
187. Negrini, M.; Calin, G.A. Breast cancer metastasis: a microRNA story. *Breast Cancer Res*, **2008**, 10(2), 203.
188. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A*, **2006**, 103(7), 2257-2261.
189. Huang, Q.; Gumireddy, K.; Schrier, M.; le Sage, C.; Nagel, R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nat Cell Biol*, **2008**, 10(2), 202-210.
190. You, L.; An, R.; Wang, X.; Li, Y. Discovery of novel osthole derivatives as potential anti-breast cancer treatment. *Bioorg Med Chem Lett*, **2010**, 20(24), 7426-7428.
191. Hung, C.M.; Kuo, D.H.; Chou, C.H.; Su, Y.C.; Ho, C.T. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-

- Met/Akt/mTOR pathway in human breast cancer cells. *J Agric Food Chem*, **2011**, 59(17), 9683-9690.
192. Jiang, G.; Liu, J.; Ren, B.; Tang, Y.; Owusu, L. Anti-tumor effects of osthole on ovarian cancer cells in vitro. *J Ethnopharmacol*, **2016**, 193(368-376).
  193. Xu, X.M.; Zhang, Y.; Qu, D.; Liu, H.B.; Gu, X. Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro. *Exp Ther Med*, **2013**, 5(3), 707-710.
  194. Liu, L.; Mao, J.; Wang, Q.; Zhang, Z.; Wu, G. In vitro anticancer activities of osthole against renal cell carcinoma cells. *Biomed Pharmacother*, **2017**, 94(1020-1027).
  195. Min, K.J.; Han, M.A.; Kim, S.; Park, J.W.; Kwon, T.K. Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells. *Oncol Rep*, **2017**, 37(4), 2348-2354.
  196. Ming, L.G.; Ge, B.F.; Chen, K.M.; Ma, H.P.; Zhai, Y.K. [Effect of Osthon on the proliferation and differentiate of osteoblasts in vitro]. *Zhongguo Gu Shang*, **2010**, 23(9), 688-691.
  197. Qin, L.P.; Zhang, Q.Y.; Tian, Y.P.; Zheng, H.C.; Haung, M. Total coumarins from fruits of *Cnidium monnieri* inhibit formation and differentiation of multinucleated osteoclasts of rats. *Acta Pharmacol Sin*, **2003**, 24(2), 181-186.
  198. Zhang, W.; Ma, D.; Zhao, Q.; Ishida, T. The effect of the major components of *Fructus Cnidii* on osteoblasts in vitro. *J Acupunct Meridian Stud*, **2010**, 3(1), 32-37.
  199. Ming, L.G.; Wang, M.G.; Chen, K.M.; Zhou, J.; Han, G.Q. [Effect of osthon on apoptosis and bone resorption of osteoclasts cultured in vitro]. *Yao Xue Xue Bao*, **2012**, 47(2), 174-179.
  200. Li, Q.N.; Liang, N.C.; Wu, T.; Wu, Y.; Xie, H. Effects of total coumarins of *Fructus cnidii* on skeleton of ovariectomized rats. *Zhongguo Yao Li Xue Bao*, **1994**, 15(6), 528-532.
  201. Tang, D.Z.; Hou, W.; Zhou, Q.; Zhang, M.; Holz, J. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. *J Bone Miner Res*, **2010**, 25(6), 1234-1245.
  202. Huang, R.L.; Chen, C.C.; Huang, Y.L.; Hsieh, D.J.; Hu, C.P. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro. *Hepatology*, **1996**, 24(3), 508-515.



203. Qi, Z.; Xue, J.; Zhang, Y.; Wang, H.; Xie, M. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. *Planta Med*, **2011**, 77(3), 231-235.
204. Shin, E.; Lee, C.; Sung, S.H.; Kim, Y.C.; Hwang, B.Y. Antifibrotic activity of coumarins from *Cnidium monnieri* fruits in HSC-T6 hepatic stellate cells. *J Nat Med*, **2011**, 65(2), 370-374.
205. Lee, W.H.; Lin, R.J.; Lin, S.Y.; Chen, Y.C.; Lin, H.M. Osthole enhances glucose uptake through activation of AMP-activated protein kinase in skeletal muscle cells. *J Agric Food Chem*, **2011**, 59(24), 12874-12881.
206. Li, L.; Zhuang, F.E.; Zhao, G.S.; Zhao, D.K. [Effects of osthole on the isolated guinea-pig ileum and taeniae coli]. *Yao Xue Xue Bao*, **1993**, 28(12), 899-904.
207. Teng, C.M.; Ko, F.N.; Wang, J.P.; Lin, C.N.; Wu, T.S. Antihaemostatic and antithrombotic effect of some antiplatelet agents isolated from Chinese herbs. *J Pharm Pharmacol*, **1991**, 43(9), 667-669.